Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

In Bridge-TIMI 73a and SHASTA-2, the RNA-silencing therapies cut triglycerides quickly, offering hope for hard-to-treat patients.

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Boston ,Massachusetts ,Philadelphia ,Canada ,Australia ,Montreal ,Quebec ,Perth ,Western Australia ,Daniel Soffer ,Brian Bergmark ,Daniel Gaudet ,Gerald Watts ,Neha Pagidipati ,Pradeep Natarajan ,Phd University Of Western Australia ,Phd University Of Montreal ,Md Duke University School Of Medicine ,Ionis Pharmaceuticals ,Md University Of Pennsylvania School Medicine ,Arrowhead Pharmaceuticals ,Drug Administration ,American College Of Cardiology ,American College ,Pennsylvania School ,Duke University School ,New England Journal ,Massachusetts General Hospital ,